Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Metastatic Pancreatic Adenocarcinoma
In brief
This protocol will enroll patients with metastatic pancreatic cancer to receive modified FOLFIRINOX plus devimistat. Patients will be enrolled with 1:1 randomization between Dose Escalation Cohort and Cohort A until required 20 patients have been enrolled on Cohort A following which randomization will end and patients will be enrolled without randomization to Dose Escalation Cohort and then subsequently to Cohort B.
Key facts
- Study ID
- NCT05926206
- Run by
- University of Michigan Rogel Cancer Center
- People needed
- 0
- Starts
- 2023-07-01
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2023-08-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rogel Cancer Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.